{"transactions":[{"id":729309,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:13:19.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000081","document":"wk-form4_1782249197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000081/wk-form4_1782249197.xml","form_type":"4"}},{"id":729308,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:13:19.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000081","document":"wk-form4_1782249197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000081/wk-form4_1782249197.xml","form_type":"4"}},{"id":814556,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:07:20.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000061","document":"wk-form4_1775506037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000061/wk-form4_1775506037.xml","form_type":"4"}},{"id":814555,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:07:20.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":3262,"price":34.71,"value":113224.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":46829,"source":{"system":"sec-edgar","filing":"0001439222-26-000061","document":"wk-form4_1775506037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000061/wk-form4_1775506037.xml","form_type":"4"}},{"id":814554,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:07:20.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50091,"source":{"system":"sec-edgar","filing":"0001439222-26-000061","document":"wk-form4_1775506037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000061/wk-form4_1775506037.xml","form_type":"4"}},{"id":868389,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8000,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":868388,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":5666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":5667,"derivative":{"underlying":"Common stock","underlying_shares":5666},"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":868387,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock options (right to buy)","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":30.23,"expiration_date":"2036-03-01","underlying":"Common stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":868386,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":14000,"derivative":{"underlying":"Common stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":868385,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1187,"price":28.96,"value":34375.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025."}],"balance_after":41591,"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":868384,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":42778,"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":868383,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1681,"price":28.96,"value":48681.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":38778,"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":868382,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:13:59.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":5666,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40459,"source":{"system":"sec-edgar","filing":"0001439222-26-000036","document":"wk-form4_1772572436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000036/wk-form4_1772572436.xml","form_type":"4"}},{"id":944812,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2026-01-07T21:23:15.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":false,"shares":8475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8475},"source":{"system":"sec-edgar","filing":"0001439222-26-000013","document":"wk-form4_1767820992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000013/wk-form4_1767820992.xml","form_type":"4"}},{"id":944811,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-01-07T21:23:15.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":2872,"price":27.02,"value":77601.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023."}],"balance_after":34793,"source":{"system":"sec-edgar","filing":"0001439222-26-000013","document":"wk-form4_1767820992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000013/wk-form4_1767820992.xml","form_type":"4"}},{"id":944810,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-01-07T21:23:15.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":true,"shares":8475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":37665,"source":{"system":"sec-edgar","filing":"0001439222-26-000013","document":"wk-form4_1767820992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000013/wk-form4_1767820992.xml","form_type":"4"}},{"id":955340,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2026-01-03T01:15:02.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001439222-26-000004","document":"wk-form4_1767402899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000004/wk-form4_1767402899.xml","form_type":"4"}},{"id":955339,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:15:02.000Z","date":"2025-12-30","kind":"sale","planned":true,"acquired":false,"shares":2932,"price":27.09,"value":79427.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":29190,"source":{"system":"sec-edgar","filing":"0001439222-26-000004","document":"wk-form4_1767402899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000004/wk-form4_1767402899.xml","form_type":"4"}},{"id":955338,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:15:02.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32122,"source":{"system":"sec-edgar","filing":"0001439222-26-000004","document":"wk-form4_1767402899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000004/wk-form4_1767402899.xml","form_type":"4"}},{"id":1101174,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2025-06-26T21:23:16.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":6000,"derivative":{"underlying":"Common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001439222-25-000065","document":"wk-form4_1750972990.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000065/wk-form4_1750972990.xml","form_type":"4"}},{"id":1101173,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:23:16.000Z","date":"2025-06-24","kind":"sale","planned":true,"acquired":false,"shares":2770,"price":33.54,"value":92905.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":26122,"source":{"system":"sec-edgar","filing":"0001439222-25-000065","document":"wk-form4_1750972990.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000065/wk-form4_1750972990.xml","form_type":"4"}},{"id":1101172,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:23:16.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28892,"source":{"system":"sec-edgar","filing":"0001439222-25-000065","document":"wk-form4_1750972990.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000065/wk-form4_1750972990.xml","form_type":"4"}},{"id":1229693,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:12:59.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":5667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11333,"derivative":{"underlying":"Common stock","underlying_shares":5667},"source":{"system":"sec-edgar","filing":"0001439222-25-000017","document":"wk-form4_1741122771.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000017/wk-form4_1741122771.xml","form_type":"4"}},{"id":1229692,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-03-04T21:12:59.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":43500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":43500,"derivative":{"exercise_price":35.54,"expiration_date":"2035-03-01","underlying":"Common stock","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001439222-25-000017","document":"wk-form4_1741122771.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000017/wk-form4_1741122771.xml","form_type":"4"}},{"id":1229691,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:12:59.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":12000,"derivative":{"underlying":"Common stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001439222-25-000017","document":"wk-form4_1741122771.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000017/wk-form4_1741122771.xml","form_type":"4"}},{"id":1229690,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:12:59.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":1681,"price":35.54,"value":59742.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":22892,"source":{"system":"sec-edgar","filing":"0001439222-25-000017","document":"wk-form4_1741122771.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000017/wk-form4_1741122771.xml","form_type":"4"}},{"id":1229689,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:12:59.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":5667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24573,"source":{"system":"sec-edgar","filing":"0001439222-25-000017","document":"wk-form4_1741122771.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000017/wk-form4_1741122771.xml","form_type":"4"}},{"id":1308367,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2025-01-07T22:05:04.000Z","date":"2025-01-03","kind":"exercise","planned":true,"acquired":false,"shares":8476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8475,"derivative":{"underlying":"Common stock","underlying_shares":8476},"source":{"system":"sec-edgar","filing":"0001439222-25-000002","document":"wk-form4_1736287498.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000002/wk-form4_1736287498.xml","form_type":"4"}},{"id":1308366,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2025-01-07T22:05:04.000Z","date":"2025-01-06","kind":"sale","planned":true,"acquired":false,"shares":2804,"price":32.18,"value":90232.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023."}],"balance_after":18906,"source":{"system":"sec-edgar","filing":"0001439222-25-000002","document":"wk-form4_1736287498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000002/wk-form4_1736287498.xml","form_type":"4"}},{"id":1308365,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2025-01-07T22:05:04.000Z","date":"2025-01-03","kind":"exercise","planned":true,"acquired":true,"shares":8476,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21710,"source":{"system":"sec-edgar","filing":"0001439222-25-000002","document":"wk-form4_1736287498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922225000002/wk-form4_1736287498.xml","form_type":"4"}},{"id":1597692,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock options (right to buy)","published_at":"2024-03-05T21:06:38.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":60000,"derivative":{"exercise_price":32.27,"expiration_date":"2034-03-01","underlying":"Common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001439222-24-000044","document":"wk-form4_1709672778.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000044/wk-form4_1709672778.xml","form_type":"4"}},{"id":1597691,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:06:38.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":17000,"derivative":{"underlying":"Common stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001439222-24-000044","document":"wk-form4_1709672778.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000044/wk-form4_1709672778.xml","form_type":"4"}},{"id":1672242,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2024-01-24T21:19:23.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":false,"shares":5448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on January 3, 2023. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on January 3, 2023. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":5448},"source":{"system":"sec-edgar","filing":"0001439222-24-000012","document":"wk-form4_1706131154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000012/wk-form4_1706131154.xml","form_type":"4"}},{"id":1672241,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:19:23.000Z","date":"2024-01-24","kind":"sale","planned":true,"acquired":false,"shares":1618,"price":21.64,"value":35013.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023."}],"balance_after":13234,"source":{"system":"sec-edgar","filing":"0001439222-24-000012","document":"wk-form4_1706131154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000012/wk-form4_1706131154.xml","form_type":"4"}},{"id":1672240,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:19:23.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":true,"shares":5448,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14852,"source":{"system":"sec-edgar","filing":"0001439222-24-000012","document":"wk-form4_1706131154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000012/wk-form4_1706131154.xml","form_type":"4"}},{"id":1685808,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2024-01-05T21:10:37.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":false,"shares":8475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":16951,"derivative":{"underlying":"Common stock","underlying_shares":8475},"source":{"system":"sec-edgar","filing":"0001439222-24-000002","document":"wk-form4_1704489026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000002/wk-form4_1704489026.xml","form_type":"4"}},{"id":1685807,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2024-01-05T21:10:37.000Z","date":"2024-01-05","kind":"sale","planned":true,"acquired":false,"shares":2902,"price":22.32,"value":64772.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023."}],"balance_after":9404,"source":{"system":"sec-edgar","filing":"0001439222-24-000002","document":"wk-form4_1704489026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000002/wk-form4_1704489026.xml","form_type":"4"}},{"id":1685806,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2024-01-05T21:10:37.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":true,"shares":8475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12306,"source":{"system":"sec-edgar","filing":"0001439222-24-000002","document":"wk-form4_1704489026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922224000002/wk-form4_1704489026.xml","form_type":"4"}},{"id":1841271,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2023-06-30T20:02:40.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":false,"shares":5449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":5448,"derivative":{"underlying":"Common stock","underlying_shares":5449},"source":{"system":"sec-edgar","filing":"0001439222-23-000099","document":"wk-form4_1688155347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922223000099/wk-form4_1688155347.xml","form_type":"4"}},{"id":1841270,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:02:40.000Z","date":"2023-06-30","kind":"sale","planned":true,"acquired":false,"shares":1618,"price":28.36,"value":45886.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units."}],"balance_after":3831,"source":{"system":"sec-edgar","filing":"0001439222-23-000099","document":"wk-form4_1688155347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922223000099/wk-form4_1688155347.xml","form_type":"4"}},{"id":1841269,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:02:40.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":true,"shares":5449,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5449,"source":{"system":"sec-edgar","filing":"0001439222-23-000099","document":"wk-form4_1688155347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922223000099/wk-form4_1688155347.xml","form_type":"4"}},{"id":2063218,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2023-01-05T21:11:00.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":25426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":25426,"derivative":{"underlying":"Common stock","underlying_shares":25426},"source":{"system":"sec-edgar","filing":"0001439222-23-000004","document":"wf-form4_167295304325378.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922223000004/wf-form4_167295304325378.xml","form_type":"4"}},{"id":2063217,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2023-01-05T21:11:00.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":135682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 3, 2023. The shares underlying this option vest as to 25% of the underlying shares on January 3, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":135682,"derivative":{"exercise_price":27.53,"expiration_date":"2033-01-03","underlying":"Common stock","underlying_shares":135682},"source":{"system":"sec-edgar","filing":"0001439222-23-000004","document":"wf-form4_167295304325378.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922223000004/wf-form4_167295304325378.xml","form_type":"4"}}]}